Literature DB >> 29383573

Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management.

Helia Ghanean1, Amanda K Ceniti2,3, Sidney H Kennedy4,5,6,7,8,9.   

Abstract

Fatigue is a frequently reported symptom in major depressive disorder, occurring in over 90% of patients. Clinical presentations of fatigue within major depressive disorder encompass overlapping physical, cognitive and emotional aspects. While this review addresses the epidemiology, burden, functional impact and management of fatigue in major depressive disorder, the main focus is on available pharmacotherapy options and their comparative efficacies. Our review of the effects of pharmacological treatments on fatigue in major depressive disorder found that medications with dopaminergic and/or noradrenergic action such as modafinil, flupenthixol and atomoxetine were most effective in improving symptoms of fatigue and low energy. However, significant variation across studies in assessment tools and study inclusion/exclusion criteria may have contributed to inconsistent findings. The efficacy of non-pharmacological interventions is also discussed, including light therapy and exercise.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29383573     DOI: 10.1007/s40263-018-0490-z

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  62 in total

1.  Fatigue: time to recognise and deal with an old problem.

Authors:  A M Feyer
Journal:  BMJ       Date:  2001-04-07

2.  Associations among smoking, anhedonia, and reward learning in depression.

Authors:  Gabrielle I Liverant; Denise M Sloan; Diego A Pizzagalli; Christopher B Harte; Barbara W Kamholz; Laina E Rosebrock; Andrew L Cohen; Maurizio Fava; Gary B Kaplan
Journal:  Behav Ther       Date:  2014-02-13

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 4.  The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.

Authors:  David Nutt; Koen Demyttenaere; Zoltan Janka; Trond Aarre; Michel Bourin; Pier Luigi Canonico; Jose Luis Carrasco; Steven Stahl
Journal:  J Psychopharmacol       Date:  2006-10-18       Impact factor: 4.153

5.  Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study.

Authors:  H J Conradi; J Ormel; P de Jonge
Journal:  Psychol Med       Date:  2010-10-08       Impact factor: 7.723

6.  Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction.

Authors:  Madelon Y Bolling; Robert J Kohlenberg
Journal:  Psychother Psychosom       Date:  2004 Nov-Dec       Impact factor: 17.659

7.  Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Arun V Ravindran; Sidney H Kennedy; M Claire O'Donovan; Angelo Fallu; Fernando Camacho; Carin E Binder
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384

8.  What are 'good' depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis.

Authors:  Eiko I Fried; Sacha Epskamp; Randolph M Nesse; Francis Tuerlinckx; Denny Borsboom
Journal:  J Affect Disord       Date:  2015-10-01       Impact factor: 4.839

9.  Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.

Authors:  Helen Bould; Nicola Wiles; John Potokar; Philip Cowen; David J Nutt; Tim J Peters; Glyn Lewis
Journal:  J Psychopharmacol       Date:  2012-01-04       Impact factor: 4.153

10.  Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression.

Authors:  Janina M Burschka; Philipp M Keune; Ulrich Hofstadt-van Oy; Patrick Oschmann; Peter Kuhn
Journal:  BMC Neurol       Date:  2014-08-23       Impact factor: 2.474

View more
  11 in total

Review 1.  Vigor, Effort-Related Aspects of Motivation and Anhedonia.

Authors:  Michael T Treadway; John D Salamone
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding.

Authors:  Renee A Rotolo; Predrag Kalaba; Vladimir Dragacevic; Rose E Presby; Julia Neri; Emily Robertson; Jen-Hau Yang; Merce Correa; Vasiliy Bakulev; Natalia N Volkova; Christian Pifl; Gert Lubec; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2020-08-07       Impact factor: 4.530

3.  Addressing sleep problems and fatigue within child and adolescent mental health services: A qualitative study.

Authors:  Nina Higson-Sweeney; Maria Elizabeth Loades; Rachel Hiller; Rebecca Read
Journal:  Clin Child Psychol Psychiatry       Date:  2019-04-08       Impact factor: 2.544

Review 4.  Gut Microbiota in Alzheimer's Disease, Depression, and Type 2 Diabetes Mellitus: The Role of Oxidative Stress.

Authors:  Maria Luca; Maurizio Di Mauro; Marco Di Mauro; Antonina Luca
Journal:  Oxid Med Cell Longev       Date:  2019-04-17       Impact factor: 6.543

5.  Fatigue and brain arousal in patients with major depressive disorder.

Authors:  Galina Surova; Christine Ulke; Frank Martin Schmidt; Tilman Hensch; Christian Sander; Ulrich Hegerl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-12-04       Impact factor: 5.270

6.  Prevalence and correlates of fatigue and its association with quality of life among clinically stable older psychiatric patients during the COVID-19 outbreak: a cross-sectional study.

Authors:  Siyun Zou; Zi-Han Liu; Xiaona Yan; Huan Wang; Yulong Li; Xiuying Xu; Xiangdong Du; Lan Zhang; Qinge Zhang; Todd Jackson; Gabor S Ungvari; Yu-Tao Xiang
Journal:  Global Health       Date:  2020-12-18       Impact factor: 4.185

7.  Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study.

Authors:  Bernhard T Baune; Ioana Florea; Bjarke Ebert; Maëlys Touya; Anders Ettrup; Monica Hadi; Hongye Ren
Journal:  Neuropsychiatr Dis Treat       Date:  2021-09-23       Impact factor: 2.570

8.  A Systematic Review and Individual Patient Data Network Analysis of the Residual Symptom Structure Following Cognitive-Behavioral Therapy and Escitalopram, Mirtazapine and Venlafaxine for Depression.

Authors:  Aoife Whiston; Amy Lennon; Catherine Brown; Chloe Looney; Eve Larkin; Laurie O'Sullivan; Nurcan Sik; Maria Semkovska
Journal:  Front Psychiatry       Date:  2022-02-01       Impact factor: 4.157

9.  Effects of Lower Limb Cycling Training on Different Components of Force and Fatigue in Individuals With Parkinson's Disease.

Authors:  Yen-Po Lin; Rou-Shayn Chen; Vincent Chiun-Fan Chen; Chun-Hsien Liu; Hsiao-Lung Chan; Ya-Ju Chang
Journal:  Front Bioeng Biotechnol       Date:  2022-03-02

10.  Moxibustion at 'Danzhong' (RN17) and 'Guanyuan' (RN4) for fatigue symptom in patients with depression: Study protocol clinical trial (SPIRIT Compliant).

Authors:  Somayeh Iravani; Liwei Cai; Lue Ha; Shuzhe Zhou; Chuan Shi; Yibin Ma; Qin Yao; Ke Xu; Baixiao Zhao
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.